Melanoma & Skin Cancers

NewsMore ›

Nivolumab approved as first-line, single agent for advanced melanoma
Nivolumab, a programmed death receptor–1 (PD-1) blocking antibody, has been approved as a single agent for the first-line treatment of patients with BRAF V600 wild-type... More »

Dermatologists’ management of melanoma varies
CHICAGO – Significant variance exists in management of primary cutaneous melanoma, according to a national survey of 510 dermatologists. Most dermatologists (36%) preferred... More »

Immune-related events with checkpoint inhibitors are manageable
BOSTON– Immune-related adverse events associated with checkpoint inhibitor therapy are generally mild to moderate and transient, but some less common side effects can be... More »

CommentaryMore ›
Dr. Gideon Blumenthal

Immune-related patterns of response present challenges
With the race to develop cancer immunotherapies escalating and new agents appearing in the clinic, oncologists’ decision-making toolbox will need to evolve. “As... More »

Point/Counterpoint: What is the first-line treatment of choice for metastatic BRAF-mutant melanoma?
Dr. Mario Sznol and Dr. Jeffrey Sosman debate immunotherapy vs. BRAF-targeted therapy.

Mini X-Ray Device Treats Nonmelanoma Skin Cancers
MIAMI BEACH – An x-ray tube about the size of a sewing needle can safely deliver radiation to nonmelanoma skin tumors on the nose, scalp, or other highly visible areas of... More »

  Patient ResourcesMore ›

Decision Support in Medicine: Melanoma
Melanoma occurs in over 764,000 individuals in the U.S. annually, with over 9,700 deaths. If diagnosed early, melanoma is easily cured. The AJCC staging provides valuable... More »

VideoMore ›

VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?
CHICAGO – Combining the immunotherapy antibodies nivolumab and ipilimumab induced more robust responses in untreated advanced melanoma when used together than as single... More »

VIDEO: Lymphadenectomies don’t boost survival in melanoma with SLN micrometastases
CHICAGO – Complete lymph node dissection did not improve survival in a prospective, randomized trial of 483 patients with stage III melanoma and micrometastases in their... More »

VIDEO: Updating the immune response to nonmelanoma skin cancer
ASHEVILLE, N.C. – Recent advances in basic science have shown how the local immune environment in tissue surrounding nonmelanoma skin cancer compares to adjacent normal... More »